Considering India’s ‘Pharmacy of the World’ stature, what are the primary drivers propelling its pharmaceutical industry, and how has Lupin specifically contributed to this global prominence?
India’s stature as the ‘Pharmacy of the World’ is driven by its unmatched capability in manufacturing high-quality, affordable medicines at scale. This growth is supported by our strong expertise in generics, a robust manufacturing ecosystem that adheres to global regulatory standards, deep scientific and R&D talent, and a resilient supply chain. These features have positioned India as the largest supplier of generics globally and a prominent exporter of vaccines and essential pharmaceuticals.

With 15 manufacturing plants and 7 research facilities, Lupin has consistently contributed to this journey. We have a strong presence in India, North America, EMEA, and APAC, offering products in over 100 countries. Lupin’s leadership in cardiovascular, respiratory, and diabetes therapies and pioneering work in complex generics and biosimilars has helped strengthen India’s global pharmaceutical presence. Beyond products, our consistent focus on quality, patient-centric innovation, and partnerships across geographies to provide quality medicines and expand access while delivering on the promise of affordable healthcare worldwide. In doing so, Lupin continues to play an integral role in reinforcing India’s reputation as a trusted healthcare partner to the world.

The total market size of the Indian Pharma Industry is expected to reach US$ 130 billion by 2030 and US$ 450 billion market by 2047. According to you, what have been the key achievements of the industry to support these projections?
Over the past two decades, the Indian pharmaceutical industry has demonstrated remarkable progress, establishing itself as a global powerhouse in generics and biosimilars. India supplies nearly 20% of the world’s generic medicines by volume, making it the largest provider worldwide. It also fulfils about 55-60% of global vaccine demand. The sector has achieved notable progress in complex generics, as demonstrated by successful introductions within inhalation and injectable categories that necessitate advanced manufacturing capabilities.

India has the largest number of U.S. FDA-approved facilities outside the United States, ensuring adherence to international quality standards. India’s pharmaceutical ecosystem has benefited from robust R&D investments, digital technology adoption, and advanced manufacturing practices. Government initiatives like the Production Linked Incentive (PLI) scheme and regulatory reforms have further catalyzed industry growth. The resilience of supply chains, demonstrated during the pandemic, reinforced India’s reputation as a reliable healthcare partner.

However, the industry continues to face challenges such as ensuring consistent quality across all manufacturers, reducing reliance on imported APIs, complex regulatory requirements, and evolving global standards.

The industry should invest in research and development, boost domestic API production, and build international partnerships to reach a market size of US$130 billion by 2030 and US$450 billion by 2047. Ongoing policy support, innovation, and active collaboration with global regulators are vital for India to achieve its goal of being the ‘Pharmacy of the World’ and promote inclusive healthcare.

What are the key factors driving the growth of OTC segment in India?
The OTC market in India is witnessing robust growth driven by multiple factors. Rising health awareness, supported by higher disposable income and lifestyle changes, has boosted the demand for preventive healthcare and wellness solutions. The growing preference for self-care and urbanization has significantly increased the adoption of OTC products such as vitamins and supplements.

The expansion of retail networks, alongside the rapid growth of e-pharmacies and digital health platforms, has significantly enhanced accessibility nationwide.

Additionally, the rise of e-commerce and telemedicine has further improved access to and the convenience of OTC products. The market continues to benefit from ongoing product innovation and increased investment in research and development (R&D). Regulatory reforms and the progressive transition of prescription (Rx) products to over-the-counter (OTC) status have also broadened product availability.

How has your company expanded its focus on consumer health and OTC products in recent years, and what opportunities do you see in this segment?
Lupin Life Consumer Healthcare adopts a science-driven, consumer-centric methodology across prominent OTC domains such as gastrointestinal health, vitamins, pain management, and emerging fields, including women’s and children’s health.

The organisation employs targeted, research-informed strategies to identify and address market gaps, focusing on integrating consumer insights to deliver efficacious wellness solutions. Through accelerated expansion and enhanced market penetration, Lupin endeavours to reinforce its dedication to accessible and evidence-based healthcare.

Given the rise in health awareness, how are you addressing evolving consumer preferences in categories like women’s health, nutraceuticals, and fitness supplements in OTC segment, and how do you see these contributing to your business growth?
As health awareness continues to rise, we see a clear shift in consumer expectations, especially in women’s health, nutraceuticals, and fitness supplements within the OTC segment. To address these evolving preferences, we have adopted a comprehensive strategy.

First, we are expanding our OTC portfolio with innovative, science-backed products catering to the unique needs of women and health-conscious consumers. This includes developing targeted solutions for different life stages, advanced nutraceuticals and fitness supplements that support holistic well-being.

Second, we are leveraging digital platforms and data analytics to understand consumer trends better and enhance accessibility. By partnering with leading e-commerce channels and investing in digital health initiatives, we are making it easier for consumers to access our products and receive support, no matter where they are.

These initiatives are not only helping us meet the changing needs of our consumers but are also driving our business growth. By strengthening our presence in these high-potential segments, we are reaching new audiences, building stronger brand loyalty, and reinforcing our position as a trusted leader in health and wellness.

What are the major challenges in consumer health and OTC product lines, and how are you addressing these challenges?
The OTC market in India is highly cluttered and competitive. Hence, a major opportunity lies in staying ahead of the curve by identifying and catering to rapidly evolving consumer needs and preferences. As consumers seek more personalized solutions and prioritize convenience, it becomes essential for us to stand out in this saturated market. We have carved out the OTC business into a wholly owned subsidiary—LupinLife Consumer Healthcare—to sharpen operational focus, accelerate innovation, and respond with agility to dynamic consumer needs.

Lupin Life’s portfolio includes trusted brands like Softovac, Beplex, Aptivate, Corcium, etc., which are category leaders. We are already focusing on launching differentiated products and bringing product innovation to customers.

To address this opportunity, we have also invested in omnichannel marketing, digital outreach and leveraging an e-commerce platform to improve our coverage. We also invest in optimizing our supply chain and distribution networks, enabling us to scale efficiently and maintain broad accessibility.

What are your company’s future for expanding into new or existing categories within the consumer health market?
Our growth strategy leverages a balanced combination of organic and inorganic initiatives designed to address evolving consumer health needs.

On the organic side, we are expanding our portfolio through Rx-to-OTC transitions, supported by scientific studies to ensure safety and efficacy. We are further strengthening established brands such as Softovac and Aptivate, while exploring entry into new markets with products that offer differentiated value in large and underserved segments.

We have also allocated resources to advance our branding and innovation initiatives. These measures encompass strategic marketing campaigns, digital outreach programmes, and the creation of product formats aimed at strengthening consumer engagement and fostering trust.

In terms of inorganic growth, we remain receptive to strategic acquisitions that align with our mission and complement our existing offerings. Such opportunities enable us to accelerate growth, diversify into new categories, and realize synergies across markets.